Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3757280 | 0.73 | CYP3A4 (0.52) | RAPGEF4CYP1A2GAA | |
| SCHEMBL5609447 | 0.73 | ALDH1A1 (0.58) | CYP1A2LMNAGAAMAPK1HTT | |
| SCHEMBL5004546 | 0.73 | ALDH1A1 (0.36) | CYP1A2LMNAMAPK1 | |
| SCHEMBL3123299 | 0.73 | CA1 (0.58) | CYP1A2LMNAGAAHTT | |
| SCHEMBL394722 | 0.71 | MAPK1 (0.33) | CYP1A2LMNAGAAMAPK1HTT | |
| SCHEMBL18950483 | 0.69 | ALDH1A1 (0.53) | RAPGEF4CYP1A2MAPK1TUBB1 | |
| SCHEMBL28951 | 0.69 | RAPGEF4 (0.59) | RAPGEF4CYP1A2LMNAGAA | |
| SCHEMBL1551822 | 0.69 | RAPGEF4 (0.59) | RAPGEF4CYP1A2LMNAGAA | |
| SCHEMBL26745227 | 0.69 | RAPGEF4 (0.30) | RAPGEF4 | |
| SCHEMBL12922768 | 0.69 | ACHE (0.32) | RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 723 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130784-A1 | SUBSTITUTED 1,1,1-TRIFLUORO-3-[(BENZYL)-(PYRIMIDIN-2-YL)-AMINO]-PROPAN-2-OL COMPOUNDS | PFIZER INC. | 2010-05-27 | — | — | US | claimed |
| EP-1115693-B9 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO CO (US) | 2007-12-19 | — | — | EP | claimed |
| EP-1856060-A1 | SUBSTITUTED 1,1,1-TRIFLUORO-3-[(BENZYL)-(PYRIMIDIN-2-YL)-AMINO]-PROP AN-2-OL COMPOUNDS | Pfizer Products Inc. (US) | 2007-11-21 | — | — | EP | claimed |
| EP-1115693-B1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO CO (US) | 2007-05-02 | — | — | EP | claimed |
| US-7122536-B2 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity | PFIZER INC. (US) | 2006-10-17 | — | — | US | claimed |
| WO-2006090250-A1 | SUBSTITUTED 1,1,1-TRIFLUORO-3-[(BENZYL)-(PYRIMIDIN-2-YL)-AMINO]-PROP AN-2-OL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2006-08-31 | — | — | WO | claimed |
| US-6861561-B2 | Substituted aromatic policyclic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G. D. SEARLE & CO. (US) | 2005-03-01 | — | — | US | claimed |
| US-20050043294-A1 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-6803388-B2 | TREATING ATHEROSCLEROSIS AND CORONARY ARTERY DISEASES; STEREOSELECTIVE; CHEMICAL INTERMEDIATES | PFIZER, INC. | 2004-10-12 | — | — | US | claimed |
| US-6787570-B2 | ADMINISTERING AN AROMATIC OR HETEROAROMATIC SUBSTITUTED TERTIARYAMINE COMPOUND TO TREAT ATHEROSCLEROSIS, DYSLIPIDEMIA, AND OTHER CORONARY ARTERY DISEASES | PFIZER, INC. | 2004-09-07 | — | — | US | claimed |
| EP-0659076-A1 | 7-((SUBSTITUTED)AMINO)-8-(((SUBSTITUTED)CARBONYL)-METHYLAMINO)-1-OXASPIRO(4,5)DECANES USEFUL IN PARKINSON'S DISEASE, DYSTONIA, AND OTHER MOVEMENT DISORDERS | WARNER-LAMBERT COMPANY (US) | 1995-06-28 | — | — | EP | claimed |
| EP-0632806-A1 | AMINOCYCLOHEXYLAMIDES FOR ANTIARRHYTHMIC AND ANAESTHETIC USES. | UNIV BRITISH COLUMBIA (CA) | 1995-01-11 | — | — | EP | claimed |
| US-5369120-A | Parkinson's disease | WARNER-LAMBERT COMPANY (US) | 1994-11-29 | — | — | US | claimed |
| US-5369105-A | Administering to humans | WARNER-LAMBERT COMPANY (US) | 1994-11-29 | — | — | US | claimed |
| US-5317028-A | 7-((substituted)amino)-8((substituted)carbonyl)-methylamino-1-oxaspiro(4,5)decanes useful in Parkinson's disease, dystonia, and other movement disorders | WARNER-LAMBERT CO. (US) | 1994-05-31 | — | — | US | claimed |
| WO-1994005284-A1 | 7-((SUBSTITUTED)AMINO)-8-(((SUBSTITUTED)CARBONYL)-METHYLAMINO)-1-OXASPIRO(4,5)DECANES USEFUL IN PARKINSON'S DISEASE, DYSTONIA, AND OTHER MOVEMENT DISORDERS | WARNER-LAMBERT COMPANY (US) | 1994-03-17 | — | — | WO | claimed |
| WO-1993019056-A1 | AMINOCYCLOHEXYLAMIDES FOR ANTIARRHYTHMIC AND ANAESTHETIC USES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1993-09-30 | — | — | WO | claimed |
| US-5063242-A | 7-((substituted)amino)-8-((substituted)carbonyl)-methylamino-1-oxaspiro[4,5]decanes as diuretics antiinflammatory, and cerebrovascular agents | WARNER-LAMBERT COMPANY (US) | 1991-11-05 | — | — | US | claimed |
| EP-0393696-A2 | 7-(Substituted)amino)-8-(substituted)Carbonyl)-methylamino-1-oxaspiro (4,5)decanes as diuretics antiinflammatory, and cerebrovascular agents | WARNER-LAMBERT COMPANY (US) | 1990-10-24 | — | — | EP | claimed |
| US-4965278-A | 7-(substituted)amino)-8-((substituted)carbonyl)-methylamino)-1-oxaspiro[4,5]decanes as diuretics antiiflammatory, and cerebrovascular agents | WARNER-LAMBERT COMPANY (US) | 1990-10-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043294-A1 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity | CETP, DBI, MTTP | RAPGEF4 3354/4885CYP1A2 2385/4885LMNA 2690/4885 |
| US-20100130784-A1 | SUBSTITUTED 1,1,1-TRIFLUORO-3-[(BENZYL)-(PYRIMIDIN-2-YL)-AMINO]-PROPAN-2-OL COMPOUNDS | APOB, LDLR, HDLBP | RAPGEF4 1696/4885CYP1A2 1077/4885LMNA 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.